Insulin Glargine; Lixisenatide Patent Expiration

Insulin Glargine; Lixisenatide is Used for improving glycemic control in type 2 diabetes mellitus patients. It was first introduced by Sanofi-Aventis Us Llc in its drug Soliqua 100/33 on Nov 21, 2016.


Insulin Glargine; Lixisenatide Patents

Given below is the list of patents protecting Insulin Glargine; Lixisenatide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Soliqua 100/33 US9950039 Insulin glargine/lixisenatide fixed ratio formulation Dec 10, 2035 Sanofi-aventis Us
Soliqua 100/33 US9717852 Cartridge holder and pen-type injector Apr 08, 2033 Sanofi-aventis Us
Soliqua 100/33 US9821032 Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin May 09, 2032 Sanofi-aventis Us
Soliqua 100/33 US10029011 Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine Nov 11, 2030 Sanofi-aventis Us
Soliqua 100/33 US9707176 Pharmaceutical composition comprising a GLP-1 agonist and methionine Nov 11, 2030 Sanofi-aventis Us
Soliqua 100/33 US10117909 Combination of an insulin and a GLP-1 agonist Oct 09, 2029 Sanofi-aventis Us
Soliqua 100/33 US9526764 Combination of an insulin and a GLP-1-agonist Oct 09, 2029 Sanofi-aventis Us
Soliqua 100/33 US7918833 Pen-type injector Sep 23, 2027 Sanofi-aventis Us
Soliqua 100/33 US8679069 Pen-type injector Apr 12, 2025 Sanofi-aventis Us
Soliqua 100/33 US8512297 Pen-type injector Sep 15, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9561331 Drive mechanisms suitable for use in drug delivery devices Aug 28, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9623189 Relating to drive mechanisms suitable for use in drug delivery devices Aug 19, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9533105 Drive mechanisms suitable for use in drug delivery devices Aug 17, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9604009 Drive mechanisms suitable for use in drug delivery devices Aug 16, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US8992486 Pen-type injector Jun 05, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9011391 Pen-type injector Mar 26, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US8556864 Drive mechanisms suitable for use in drug delivery devices Mar 03, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US8603044 Pen-type injector Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9233211 Relating to a pen-type injector Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9408979 Pen-type injector Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9526844 Pen-type injector Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9604008 Drive mechanisms suitable for use in drug delivery devices Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9610409 Drive mechanisms suitable for use in drug delivery devices Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9775954 Pen-type injector Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 US9827379 Drive mechanisms suitable for use in drug delivery devices Mar 02, 2024

(Expired)

Sanofi-aventis Us
Soliqua 100/33 USRE45313 Exendin variant peptides Jul 12, 2020

(Expired)

Sanofi-aventis Us



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Glargine; Lixisenatide's patents.

Given below is the list recent legal activities going on the following patents of Insulin Glargine; Lixisenatide.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 12 Jun, 2024 US9526764
Payment of Maintenance Fee, 4th Year, Large Entity 20 Apr, 2022 US10117909
Payment of Maintenance Fee, 4th Year, Large Entity 12 Jan, 2022 US10029011
Payment of Maintenance Fee, 4th Year, Large Entity 06 Oct, 2021 US9950039
Payment of Maintenance Fee, 4th Year, Large Entity 11 Jun, 2020 US9526764
Patent Issue Date Used in PTA Calculation 06 Nov, 2018 US10117909
Recordation of Patent Grant Mailed 06 Nov, 2018 US10117909
Issue Notification Mailed 17 Oct, 2018 US10117909
Dispatch to FDC 01 Oct, 2018 US10117909
Application Is Considered Ready for Issue 01 Oct, 2018 US10117909


Insulin Glargine; Lixisenatide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List